Transfusion-associated infections: 50 years of relentless challenges and remarkable progress

Transfusion

Volumn 50, Issue 10, 2010, Pages 2080-2099

  Perkins, Herbert A ^a   Busch, Michael P ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARBOVIRUS; BABESIOSIS; BACTERIUM CONTAMINATION; BLOOD BANK; BLOOD DONOR; BLOOD EXAMINATION; BLOOD TRANSFUSION; CHAGAS DISEASE; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS; INFECTION; INFECTION RISK; MALARIA; REVIEW; SEROLOGY; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; BABESIOSIS; BLOOD TRANSFUSION; CHAGAS DISEASE; COMMUNICABLE DISEASES; DISEASE TRANSMISSION, INFECTIOUS; HEPATITIS A; HEPATITIS B; HEPATITIS, VIRAL, HUMAN; HUMANS; SYPHILIS;

EID: 78649487218     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02851.x     Document Type: Review

References (155)

1. Orton S. Syphilis and blood donors: what we know, what we do not know, and what we need to know. Transfus Med Rev 2001;15:282-91.
2. Stansbury LG, Hess J.R. Blood transfusion inWorldWar I: the roles of Lawrence Bruce Robertson and Oswald Hope Robertson in the "most important medical advance of the war." Transfus Med Rev 2009;23:232-6.
3. Orton SL, Dodd RY, Williams AE. Absence of risk factors for false-positive test results in blood donors with a reactive test result in an automated treponemal test (PK-TP) for syphilis. Transfusion 2001;41:744-50.
4. Chambers RW, Foley HT, Schmidt PJ. Transmission of syphilis by fresh blood components. Transfusion 1969;9: 32-4.
5. FDA-CBER. Testing HCT/P donors: specific requirements. 2009. [cited 2010 August 16] Available from URL: http:// www.fda.gov/BiologicsBloodVaccines/ SafetyAvailability/ TissueSafety/ucm151757.htm
6. Zou S, Notari EP, Fang CT , Stramer SL, Dodd RY. Current value of serologic test for syphilis as a surrogate marker for blood-borne viral infections among blood donors in the United States. Transfusion 2009;49:655-61.
7. WHO. Recommendations. Screening donated blood for transfusion- transmissible infections. 2009. [cited 2010 August 16] Available from URL: http://www.who.int/ entity/bloodsafety/ScreeningDonatedBloodfor Transfusion.pdf
8. Havens W.P. Jr. Viral hepatitis. Yale J Biol Med 1961/1962; 34:314-28.
9. Krugman S, Giles JP, Hammond J. Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 1967;200: 365-73.
10. Gowland P, Fontana S, Niederhauser C, Taleghani BM. Molecular and serologic tracing of a transfusiontransmitted hepatitis A virus. Transfusion 2004;44:1555-61.
11. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004;350: 1118-29.
12. Blumberg BS, Alter HJ, Visnich SA. "New" antigen in leukemia sera. JAMA 1965;191:541-6.
13. Prince AM. An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci U S A 1968;60:814-21.
14. Biswas R, Tabor E, Hsia CC ,Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, Nemo GJ, Busch MP. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003;43:788-98.
15. Stramer SL. Pooled hepatitis B virus DNA testing by nucleic acid amplification: implementation or not. [Editorial]. Transfusion 2005;45:1242-6.
16. Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008;48: 1001-26.
17. Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006;36 Suppl 1:S23-9.
18. Zou S, Stramer SL, Notari EP, Kuhns MC, Krysztof D, Musavi F, Fang CT, Dodd RY. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009;49:1609-20.
19. Kuhns MC, Busch MP. New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods. Mol Diagn Ther 2006;10:77-91.
20. Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009;49:2454-89.
21. Cherubin CE, Prince AM. Serum hepatitis specific antigen (SH) in commercial and volunteer sources of blood. Transfusion 1971;11:25-7.
22. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975;292:767-70.
23. Aach RD, Szmuness W, Mosley JW, Hollinger FB, Kahn RA, Stevens CE, Edwards VM, Werch J. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: the transfusiontransmitted viruses study. N Engl J Med 1981;304:989-94.
24. Alter HJ, Purcell RH, Holland PV, Alling DW, Koziol DE. Donor transaminase and recipient hepatitis. Impact on blood transfusion services. JAMA 1981;246:630-4.
25. Stevens CE, Aach RD, Hollinger FB, Mosley JW, Szmuness W, Kahn R, Werch J, Edwards V. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. Ann Intern Med 1984;101:733-8.
26. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978;298:1379-83.
27. Dodd R. Donor ALT testing as means to reduce posttransfusion hepatitis. Lab Med 1982;13:562-6.
28. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, Tegtmeier GE, Bonino F, Colombo M, Lee W-S, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244: 362-4.
29. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-500.
30. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
31. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP, Stevens CE, Hollingsworth CG and the National Heart, Lung, and Blood Institute Study Group. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992;327:1906-11.
32. Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley- Eason KD, Smoak BL, Johnson LD, Lee SR, Kaplan EL. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-11.
33. Guiltinan AM, Kaidarova Z, Custer B, Custer B, Orland J, Strollo A, Cyrus S, Busch MP, Murphy EL. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008; 167:743-50.
34. Tobler LH, Bahrami SH, Kaidarova Z, Pitina L, Winkelman VK, Vanderpool SK, Guiltinan AM, Cooper S, Busch MP, Murphy EL. A case-control study of factors associated with resolution of hepatitis C viremia in former blood donors (CME). Transfusion 2010;50:1513-23.
35. Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dockter J, Giachetti C, Busch MP. Viral and host factors in early hepatitis C virus infection. Hepatology 2005;42:86-92.
36. Operskalski EA, Mosley JW, Tobler LH, Fiebig EW, Nowicki MJ, Mimms LT, Gallarda J, Phelps BH, Busch MP, Transfusion-Transmitted Viruses Study, Retrovirus Epidemiology Donor Study. HCV viral load in anti-HCVreactive donors and infectivity for their recipients. Transfusion 2003;43:1433-41.
37. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
38. Busch MP, Kleinman SH. Hepatitis C infection: recent insights relevant to transfusion safety. ISBT Sci Series 2009;4:72-9.
39. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP, National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group.Detection of HIV-1 and HCV infections among antibodynegative blood donors by nucleic acid-amplification testing. N Engl J Med 2004;351:760-8.
40. Glynn SA, Wright DJ, Kleinman SH, Hirschkorn D, Tu Y, Heldebrant C, Smith R, Giachetti C, Gallarda J, Busch MP.Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005;45:994-1002.
41. Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY, Stramer SL. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010;50:1495-504.
42. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003;43:721-9.
43. CDC. Pneumocystis carinii pneumonia among persons with hemophilia A. MMWR Morb Mortal Wkly Rep 1982; 31:365-7.
44. Hurtenbach U, Shearer GM. Germ cell-induced immune suppression in mice. Effect of inoculation of syngeneic spermatozoa on cell-mediated immune responses. J Exp Med 1982;155:1719-29.
45. Goedert JJ, Neuland CY, Wallen WC, Greene MH, Mann DL, Murray C, Strong DM, Fraumeni JF Jr, Blattner WA. Amyl nitrite may alter T lymphocytes in homosexual men. Lancet 1982;1:412-6.
46. Sonnabend J, Witkin SS, Purtilo DT. Acquired immunode- ficiency syndrome, opportunistic infections, and malignancies in male homosexuals. A hypothesis of etiologic factors in pathogenesis. JAMA 1983;249:2370-4.
47. CDC. Possible transfusion-associated acquired immune deficiency syndrome (AIDS)-California. MMWR Morb Mortal Wkly Rep 1982;31:652-4.
48. Ammann AJ, Cowan MJ, Wara DW, Weintrub P, Dritz S, Goldman H, Perkins HA.Acquired immunodeficiency in an infant: possible transmission by means of blood products. Lancet 1983;1:956-8.
49. American Association of Blood Banks, American Red Cross, Council of Community Blood Centers. Joint statement on acquired immune deficiency syndrome (AIDS) related to transfusion. January 13, 1983.Transfusion 1983; 23:87-8.
50. CDC. Prevention of acquired immune deficiency syndrome (AIDS): report of inter-agency recommendations. MMWR Morb Mortal Wkly Rep 1983;32:101-3.
51. Perkins HA, Samson S, Busch MP. How well has selfexclusion worked? Transfusion 1988;28:601-2.
52. Busch MP, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion Safety Study Group. Transfusion 1991;31:4-11.
53. Curran JW, Lawrence DN, Jaffe H, Kaplan JE, Zyla LD, Chamberland M, Weinstein R, Lui KJ, Schonberger LB, Spira TJ et al. Acquired immunodeficiency syndrome (AIDS) associated with transfusions. N Engl J Med 1984; 310:69-75.
54. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984;224:500-3.
55. Donegan E, Stuart M, Niland JC, Sacks HS, Azen SP, Dietrich SL, Faucett C, Fletcher MA, Kleinman SH, Operskalski EA, et al. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibodypositive blood donations. Ann Intern Med 1990;113:733-9.
56. Simon TL, Bankhurst AD. A pilot study of surrogate tests to prevent transmission of acquired immune deficiency syndrome by transfusion. Transfusion 1984;24:373-8.
57. Kaplan H, Kleinman S. Infection, Immunity, and Blood Transfusion. In: Dodd RY, Barker L, editors. Xvith Annual Scientific Symposium of the American Red Cross. Washington DC: Alan R. Liss; 1984. p. 297-308.
58. Pindyck J, Waldman A, Zang E, Oleszko W, Lowy M, Bianco C. Measures to decrease the risk of acquired immunodeficiency syndrome transmission by blood transfusion. Evidence of volunteer blood donor cooperation. Transfusion 1985;25:3-9.
59. Korelitz JJ, Busch MP, Williams AE. Antigen testing for human immunodeficiency virus (HIV) and the magnet effect: will the benefit of a new HIV test be offset by the numbers of higher risk, test-seeking donors attracted to blood centers? Retrovirus Epidemiology Donor Study. Transfusion 1996;36:203-8.
60. Samson S, Busch M, Ward J, Garner J, Salk S, Fernando L, Holland P, Rutherford G, Benjamin R, Perkins H. Identification of HIV-infected transfusion recipients: the utility of crossreferencing previous donor records with AIDS case reports. Transfusion 1990;30:214-8.
61. Peterman TA, Lui KJ, Lawrence DN, Allen J.R. Estimating the risks of transfusion-associated acquired immune deficiency syndrome and human immunodeficiency virus infection. Transfusion 1987;27:371-4.
62. Donegan E, Johnson D, Remedios V, Cohen S. Mass notification of transfusion recipients at risk for HIV infection. JAMA 1988;260:922-3.
63. Petersen LR, Satten GA, Dodd R, Busch M, Kleinman S, Grindon A, Lenes B. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. The HIV Seroconversion Study Group. Transfusion 1994;34:283-9.
64. Busch MP, Stramer SL. The efficiency of HIV p24 antigen screening of US blood donors: projections versus reality. Infusionsther Transfusionmed 1998;25:5-8.
65. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH, NHLBI-REDS NAT Study Group. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45:254-64.
66. Anderson SA, Yang H, Gallagher LM, O'Callaghan S, Forshee RA, Busch MP, McKenna MT, Williams I, Williams A, Kuehnert MJ, Stramer S, Kleinman S, Epstein J, Dayton AI. Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men. Transfusion 2009;49: 1102-14.
67. Murphy EL, Fridey J, Smith JW, Engstrom J, Sacher RA, Miller K, Gibble J, Stevens J, Thomson R, Hansma D, Kaplan J, Khabbaz R, Nemo G. HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II-infected blood donors. The REDS investigators. Neurology 1997;48:315-20.
68. Murphy EL, Glynn SA, Fridey J, Sacher RA, Smith JW, Wright DJ, Newman B, Gibble JW, Ameti DI, Nass CC, Schreiber GB, Nemo GJ. Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study Group. J Infect Dis 1997;176:1468-75.
69. Murphy EL, Glynn SA, Fridey J, Smith JW, Sacher RA, Nass CC, Ownby HE, Wright DJ, Nemo GJ. Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Retrovirus Epidemiology Donor Study. Arch Intern Med 1999;159:1485-91.
70. Schreiber GB, Murphy EL, Horton JA, Wright DJ, Garfein R, Chien HC, Nass CC. Risk factors for human T-cell lymphotropic virus types I and II (HTLV-I and -II) in blood donors: the Retrovirus Epidemiology Donor Study. NHLBI Retrovirus Epidemiology Donor Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:263-71.
71. Guiltinan AM, Murphy EL, Horton JA, Nass CC, McEntire RL, Watanabe K. Psychological distress in blood donors notified of HTLV-I/II infection. Retrovirus Epidemiology Donor Study. Transfusion 1998;38:1056-62.
72. Stramer SL, Foster GA, Dodd RY. Effectiveness of human T-lymphotropic virus (HTLV) recipient tracing (lookback) and the current HTLV-I and -II confirmatory algorithm, 1999 to 2004. Transfusion 2006;46:703-7.
73. Busch MP, Switzer WM, Murphy EL, Thomson R, Heneine W. Absence of evidence of infection with divergent primate T-lymphotropic viruses in United States blood donors who have seroindeterminate HTLV test results. Transfusion 2000;40:443-9.
74. Brooks JI, Merks HW, Fournier J, Boneva RS, Sandstrom PA. Characterization of blood-borne transmission of simian foamy virus. Transfusion 2007;47:162-70.
75. Lombardi VC, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS, Peterson DL, Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B, Dean M, Silverman RH, Mikovits JA. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009;326: 585-9.
76. Coffin JM, Stoye JP. Virology. A new virus for old diseases? Science 2009;326:530-1.
77. Kitchen AD, Chiodini PL. Malaria and blood transfusion. Vox Sang 2006;90:77-84.
78. Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med 2001;344:1973-8.
79. Spencer B, Steele W, Custer B, Kleinman S, Cable R, Wilkinson S, Wright D. Risk for malaria in United States donors deferred for travel to malaria-endemic areas. Transfusion 2009;49:2335-45.
80. Schmunis GA. Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries. Transfusion 1991;31:547-57.
81. Dorn PL, Perniciaro L, Yabsley MJ, Roellig DM, Balsamo G, Diaz J, Wesson D. Autochthonous transmission of Trypanosoma cruzi, Louisiana. Emerg Infect Dis 2007;13: 605-7.
82. Young C, Losikoff P, Chawla A, Glasser L, Forman E. Transfusion-acquired Trypanosoma cruzi infection. Transfusion 2007;47:540-4.
83. Shulman IA, Appleman MD, Saxena S, Hiti AL, Kirchhoff LV. Specific antibodies to Trypanosoma cruzi among blood donors in Los Angeles, California. Transfusion 1997; 37:727-31.
84. Galel SA, Kirchhoff LV. Risk factors for Trypanosoma cruzi infection in California blood donors. Transfusion 1996;36: 227-31.
85. Leiby DA, Herron RM, Jr, Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 2002;42:549-55.
86. Pirard M, Iihoshi N, Boelaert M, Basanta P, López F, Van der Stuyft P. The validity of serologic tests for Trypanosoma cruzi and the effectiveness of transfusional screening strategies in a hyperendemic region. Transfusion 2005;45:554-61.
87. Otani MM, Vinelli E, Kirchhoff LV, del Pozo A, Sands A, Vercauteren G, Sabino EC. WHO comparative evaluation of serologic assays for Chagas disease. Transfusion 2009; 49:1076-82.
88. Gorlin J, Rossmann S, Robertson G, Stallone F, Hirschler N, Nguyen KA, Gilcher R, Fernandes H, Alvey S, Ajongwen P, Contestable P, Warren H. Evaluation of a new Trypanosoma cruzi antibody assay for blood donor screening. Transfusion 2008;48:531-40.
89. Kirchhoff LV, Paredes P, Lomeli-Guerrero A, Paredes- Espinoza M, Ron-Guerrero CS, Delgado-Mejía M, Peña- Muñoz JG. Transfusion-associated Chagas disease (American trypanosomiasis) in Mexico: implications for transfusion medicine in the United States. Transfusion 2006;46:298-304.
90. Agapova M, Busch MP, Custer B. Cost-effectiveness of screening the US blood supply for Trypanosoma cruzi. Transfusion 2010 May 12;50:[Epub ahead of print].
91. Moraes-Souza H, Bordin JO. Strategies for prevention of transfusion-associated Chagas' disease. Transfus Med Rev 1996;10:161-70.
92. Johnson ST, Cable RG, Tonnetti L, Spencer B, Rios J, Leiby DA. Seroprevalence of Babesia microti in blood donors from Babesia-endemic areas of the northeastern United States: 2000 through 2007. Transfusion 2009;49: 2574-82.
93. Gubernot DM, Nakhasi HL, Mied PA, Asher DM, Epstein JS, Kumar S. Transfusion-transmitted babesiosis in the United States: summary of a workshop. Transfusion 2009; 49:2759-71.
94. Conrad PA, Kjemtrup AM, Carreno RA, Thomford J, Wainwright K, Eberhard M, Quick R, Telford SR 3rd, Herwaldt BL. Description of Babesia duncani n.sp. (Apicomplexa: Babesiidae) from humans and its differentiation from other piroplasms. Int J Parasitol 2006; 36:779-89.
95. Tonnetti L, Johnson ST, Cable RG, Rios J, Spencer B, Leiby DA. Natural history study (NHS) of Babesia microti in Connecticut blood donors. [abstract S85-030L] Transfusion 2009;49:35a-6a.
96. Mintz ED, Anderson JF, Cable RG, Hadler JL. Transfusiontransmitted babesiosis: a case report from a new endemic area. Transfusion 1991;31:365-8.
97. Grabowski EF, Giardina PJ, Goldberg D, Masur H, Read SE, Hirsch RL, Benach JL. Babesiosis transmitted by a transfusion of frozen-thawed blood. Ann Intern Med 1982;96:466-7.
98. Young C, Krause PJ. The problem of transfusiontransmitted babesiosis. Transfusion 2009;49:2548-50.
99. Geller P, Jawetz E. Experimental studies on bacterial contamination of bank blood. I. The nature of toxicity of contaminated blood. J Lab Clin Med 1954;43:696-706.
100. Kuehnert MJ, Roth VR, Haley NR, Gregory KR, Elder KV, Schreiber GB, Arduino MJ, Holt SC, Carson LA, Banerjee SN, Jarvis WR. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001;41:1493-9.
101. Hogman CF, Gong J, Hambraeus A, Johansson CS, Eriksson L. The role of white cells in the transmission of Yersinia enterocolitica in blood components. Transfusion 1992;32:654-7.
102. Benjamin RJ, Kline L, Dy BA, Kennedy J, Pisciotto P, Sapatnekar S, Mercado R, Eder AF. Bacterial contamination of whole-blood-derived platelets: the introduction of sample diversion and prestorage pooling with culture testing in the American Red Cross. Transfusion 2008;48: 2348-55.
103. Bruneau C, Perez P, Chassaigne M, Allouch P, Audurier A, Gulian C, Janus G, Boulard G, De Micco P, Salmi LR, Noel L. Efficacy of a new collection procedure for preventing bacterial contamination of whole-blood donations. Transfusion 2001;41:74-81.
104. Ness PM, Perkins HA. Transient bacteremia after dental procedures and other minor manipulations. Transfusion 1980;20:82-5.
105. von Eiff C, Becker K, Machka K, Stammer H, Peters G.Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001;344:11-6.
106. Cover TL, Aber RC. Yersinia enterocolitica. N Engl J Med 1989;321:16-24.
107. Eder AF, Kennedy JM, Dy BA, Notari EP, Weiss JW, Fang CT, Wagner S, Dodd RY, Benjamin RJ, American Red Cross Regional Blood Centers. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Transfusion 2007;47:1134-42.
108. Kleinman SH, Kamel HT, Harpool DR, Vanderpool SK, Custer B, Wiltbank TB, Nguyen KA, Tomasulo PA. Twoyear experience with aerobic culturing of apheresis and whole blood-derived platelets. Transfusion 2006;46:1787-94.
109. Fuller AK, Uglik KM, Savage WJ, Ness PM, King KE. Bacterial culture reduces but does not eliminate the risk of septic transfusion reactions to single-donor platelets. Transfusion 2009;49:2588-93.
110. Goodrich RP, Custer B, Keil S, Busch M. Defining "adequate" pathogen reduction performance for transfused blood components. Transfusion 2010;50:1827-37.
111. Zou S, Fang CT, Schonberger LB. Transfusion transmission of human prion diseases. Transfus Med Rev 2008;22: 58-69.
112. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 2006;91:221-30.
113. Turner ML, Ludlam CA. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol 2009;144:14-23.
114. Gregori L, McCombie N, Palmer D, Birch P, Sowemimo- Coker SO, Giulivi A, Rohwer RG. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 2004; 364:529-31.
115. Burdick MD, Pifat DY, Petteway SR Jr, Cai K. Clearance of prions during plasma protein manufacture. Transfus Med Rev 2006;20:57-62.
116. Zhang W, Wu J, Li Y, Carke RC, Wong T. The in vitro bioassay systems for the amplification and detection of abnormal prion PrP(Sc) in blood and tissues. Transfus Med Rev 2008;22:234-42.
117. Dodd RY. Prions and precautions: be careful for what you ask. Transfusion 2010;50:956-8.
118. Wiltshire M, Thomas S, Scott J, Hicks V, Haines M, Cookson P, Garwood M, Cardigan R. Prion reduction of red blood cells: impact on component quality. Transfusion 2009;50:970-9.
119. Biggerstaff BJ, Petersen LR. Estimated risk ofWest Nile virus transmission through blood transfusion during an epidemic in Queens, New York City. Transfusion 2002;42: 1019-26.
120. Pealer LN, Marfin AA, Petersen LR, Lanciotti RS, Page PL, Stramer SL, Stobierski MG, Signs K, Newman B, Kapoor H, Goodman JL, Chamberland ME, West Nile Virus Transmission Investigation Team. Transmission ofWest Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003;349:1236-45.
121. Busch MP, Caglioti S, Robertson EF, McAuley JD, Tobler LH, Kamel H, Linnen JM, Shyamala V, Tomasulo P, Kleinman SH. Screening the blood supply forWest Nile virus RNA by nucleic acid amplification testing. N Engl J Med 2005;353:460-7.
122. Stramer SL, Fang CT, Foster GA, Wagner AG, Brodsky JP, Dodd RY. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med 2005;353: 451-9.
123. Kleinman S, Glynn SA, Busch M, Todd D, Powell L, Pietrelli L, Nemo G, Schreiber G, Bianco C, Katz L, NHLBI Retrovirus Epidemiology Study (REDS). The 2003West Nile virus United States epidemic: the America's Blood Centers experience. Transfusion 2005;45:469-79.
124. Petersen LR, Epstein JS. Problem solved?West Nile virus and transfusion safety. N Engl J Med 2005;353:516-7.
125. Custer B, Kamel H, Kiely NE, Murphy EL, Busch MP. Associations betweenWest Nile virus infection and symptoms reported by blood donors identified through nucleic acid test screening. Transfusion 2009;49:278-88.
126. Orton SL, Stramer SL, Dodd RY. Self-reported symptoms associated withWest Nile virus infection in RNA-positive blood donors. Transfusion 2006;46:272-7.
127. Brown JA, Factor DL, Tkachenko N, Templeton SM, Crall ND, Pape WJ, Bauer MJ, Ambruso DR, Dickey WC, Marfin AA. West Nile viremic blood donors and risk factors for subsequentWest Nile fever. Vector Borne Zoonotic Dis 2007;7:479-88.
128. Kleinman SH, Williams JD, Robertson G, Caglioti S, Williams RC, Spizman R, Morgan L, Tomasulo P, Busch MP. West Nile virus testing experience in 2007: evaluation of different criteria for triggering individual-donation nucleic acid testing. Transfusion 2009;49:1160-70.
129. CDC. West Nile virus transmission through blood transfusion-South Dakota, 2006. MMWR Morb Mortal Wkly Rep 2007;56:76-9.
130. Busch MP, Kleinman SH, Tobler LH, Kamel HT, Norris PJ, Walsh I, Matud JL, Prince HE, Lanciotti RS, Wright DJ, Linnen JM, Caglioti S. Virus and antibody dynamics in acute west nile virus infection. J Infect Dis 2008;198:984-93.
131. Biggerstaff BJ, Petersen LR. A modeling framework for evaluation and comparison of trigger strategies for switching from minipool to individual-donation testing forWest Nile virus. Transfusion 2009;49:1151-9.
132. Custer B, Busch MP, Marfin AA, Petersen LR. The costeffectiveness of screening the U.S. blood supply forWest Nile virus. Ann Intern Med 2005;143:486-92.
133. Petersen LR, Hayes EB. West Nile virus in the Americas. Med Clin North Am 2008;92:1307-22. ix.
134. CDC. Transmission of Colorado tick fever virus by blood transfusion. MMWR Morb Mortal Wkly Rep 1975;24:422-7.
135. Tambyah PA, Koay ES, Poon ML, Lin RV, Ong BK; Transfusion-Transmitted Dengue Infection Study Group. Dengue hemorrhagic fever transmitted by blood transfusion. N Engl J Med 2008;359:1526-7.
136. Chuang VW, Wong TY, Leung YH, Ma ES, Law YL, Tsang OT, Chan KM, Tsang IH, Que TL, Yung RW, Liu SH. Review of dengue fever cases in Hong Kong during 1998 to 2005. Hong Kong Med J 2008;14:170-7.
137. Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet 2008;371:1861-71.
138. Kaiser R. Tick-borne encephalitis. Infect Dis Clin North Am 2008;22:561-75. x.
139. Petersen LR, Busch MP. Transfusion-transmitted arboviruses. Vox Sang 2009;98:495-503.
140. Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res 2002; 33:330-42.
141. Linnen JM, Vinelli E, Sabino EC, Tobler LH, Hyland C, Lee TH, Kolk DP, Broulik AS, Collins CS, Lanciotti RS, Busch MP. Dengue viremia in blood donors from Honduras, Brazil, and Australia. Transfusion 2008;48:1355-62.
142. Mohammed H, Linnen JM, Munoz-Jordan JL, Tomashek K, Foster G, Broulik AS, Petersen L, Stramer SL. Dengue virus in blood donations, Puerto Rico, 2005. Transfusion 2008;48:1348-54.
143. Bianco C. Dengue and Chikungunya viruses in blood donations: risks to the blood supply? Transfusion 2008;48: 1279-81.
144. Delwart EL. Viral metagenomics. Rev Med Virol 2007;17: 115-31.
145. Bernardin F, Operskalski E, Busch M, Delwart E. Transfusion transmission of highly prevalent commensal human viruses. Transfusion 2010 May 24;50:[Epub ahead of print].
146. Cannon MJ, Operskalski EA, Mosley JW, Radford K, Dollard SC. Lack of evidence for human herpesvirus-8 transmission via blood transfusion in a historical US cohort. J Infect Dis 2009;199:1592-8.
147. Busch MP, Glynn SA. Use of blood-donor and transfusion-recipient biospecimen repositories to address emerging blood-safety concerns and advance infectious disease research: the National Heart, Lung, and Blood Institute Biologic Specimen Repository. J Infect Dis 2009; 199:1564-6.
148. Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dodd RY. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009;49 Suppl 2:1S-29S.
149. Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010 May 24;50:[Epub ahead of print].
150. Bryant BJ, Klein HG. Pathogen inactivation: the definitive safeguard for the blood supply. Arch Pathol Lab Med 2007;131:719-33.
151. Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007;47: 2338-47.
152. Alter HJ. Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev 2008;22:97-102.
153. Klein HG, Glynn SA, Ness PM, Blajchman M.A. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. Transfusion 2009;49:1262-8.
154. Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008;112:2617-26.
155. Busch MP. Transfusion-transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis. 2005 Emily Cooley Award Lecture. Transfusion 2006;46:1624-40.